Sparks commentary - Biomea Fusion

Healthcare

Sparks - Biomea Fusion

More on this equity
Biomea Fusion’s (NASDAQ: BMEA) icovamenib shows promise in severe insulin-deficient diabetes
Published by Arron Aatkar, PhD

Biomea Fusion has reported new preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 conference. Notably, the data showed that, three months after the final dose of icovamenib, patients showed significant improvements in pancreatic beta-cell function, associated with a mean increase of 53% in C-peptide levels (a measure of glucose-dependent insulin secretion). The sustained effects of the therapy post-treatment highlight the potential of icovamenib as a possible disease-modifying treatment option for patients with severe insulin-deficient diabetes.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.